ConductScience.org, home

Paper24979481

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.

Kunath F and 7 others. Cochrane Database Syst Rev, 2014. Cited by 42 papers, by iCite.

Cite this record

ConductScience Library. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Papers, record 24979481. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24979481

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
PubMed
Journal
Cochrane Database Syst Rev
PubMed
Year
2014
PubMed
Publication types
Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review
PubMed
Citations, by iCite
42
iCite
Relative citation ratio, by iCite
1.23
iCite
Revised in PubMed
2026-01-28
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kunath FFrank
2Grobe HRHenrik R
3Rücker GGerta
4Motschall EEdith
5Antes GGerd
6Dahm PPhilipp
7Wullich BBernd
8Meerpohl JJJoerg J

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Androgen AntagonistsMajor topic
Antineoplastic Agents, HormonalMajor topic
Gonadotropin-Releasing HormoneMajor topic
OrchiectomyMajor topic
Prostatic NeoplasmsMajor topic
Anilides
Disease Progression
Flutamide
Goserelin
Humans
Leuprolide
Male
Nitriles
Randomized Controlled Trials as Topic
Tosyl Compounds
Triptorelin Pamoate
Drug Monitoring

Source PubMed

Download CSV of topics

References160

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122562608Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden.Eur J Clin Pharmacol2012https://conductscience.org/library/papers/22562608PubMed
217102802Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.Prostate Cancer Prostatic Dis2007https://conductscience.org/library/papers/17102802PubMed
316822873Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months.J Clin Pathol2007https://conductscience.org/library/papers/16822873PubMed
412111919Quantifying heterogeneity in a meta-analysis.Stat Med2002https://conductscience.org/library/papers/12111919PubMed
517692108Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer.Clin Endocrinol (Oxf)2008https://conductscience.org/library/papers/17692108PubMed
68973848Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma.Clin Oncol (R Coll Radiol)1996https://conductscience.org/library/papers/8973848PubMed
717991545Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.Urology2007https://conductscience.org/library/papers/17991545PubMed
822147380Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.JAMA2011https://conductscience.org/library/papers/22147380PubMed
922498209Conflict of interest in urology.J Urol2012https://conductscience.org/library/papers/22498209PubMed
109471040
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
Eur Urol1998https://conductscience.org/library/papers/9471040PubMed
119510340
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
Urology1998https://conductscience.org/library/papers/9510340PubMed
1216430622Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.BJU Int2006https://conductscience.org/library/papers/16430622PubMed
1317332110Conflict of interest in orthopaedic research. An association between findings and funding in scientific presentations.J Bone Joint Surg Am2007https://conductscience.org/library/papers/17332110PubMed
143798631Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate.Urology1987https://conductscience.org/library/papers/3798631PubMed
1511489683Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.Urology2001https://conductscience.org/library/papers/11489683PubMed
1615540740
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.
J Urol2004https://conductscience.org/library/papers/15540740PubMed
1716858161Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial.Am J Ther2006https://conductscience.org/library/papers/16858161PubMed
1811098244Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.Evid Rep Technol Assess (Summ)1999https://conductscience.org/library/papers/11098244PubMed
198708714Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.J Clin Oncol1996https://conductscience.org/library/papers/8708714PubMed
2011905923Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.J Urol2002https://conductscience.org/library/papers/11905923PubMed

See all 160 referencesDownload CSV of references

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.

PMIDTitleJournalYearIn PapersSource
39154013Telomerase related molecular subtype and risk model reveal immune activity and evaluate prognosis and immunotherapy response in prostate cancer.Cancer Cell Int2024https://conductscience.org/library/papers/39154013PubMed
39062524Design, Synthesis, Characterization, and Cytotoxicity of New Pyrazolylmethylene-2-thioxoimidazolidin-4-one Derivatives towards Androgen-Sensitive LNCaP Prostate Cancer Cells.Biomolecules2024https://conductscience.org/library/papers/39062524PubMed
38298446Long-term disease stability with bicalutamide in a man with aggressive angiomyxoma: case report and state of art.Front Oncol2023https://conductscience.org/library/papers/38298446PubMed
37092584Prostate malignant tumor and benign prostatic hyperplasia microenvironments in black African men: Limited infiltration of CD8+ T lymphocytes, NK-cells, and high frequency of CD73+ stromal cells.Cancer Rep (Hoboken)2023https://conductscience.org/library/papers/37092584PubMed
35582006Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators.Cancer Drug Resist2021https://conductscience.org/library/papers/35582006PubMed
35118979Misconduct in research integrity: Assessment the quality of systematic reviews in Cochrane urological cancer review group.Turk J Urol2021https://conductscience.org/library/papers/35118979PubMed
35017008Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial.Int J Radiat Oncol Biol Phys2022https://conductscience.org/library/papers/35017008PubMed
34692585Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study.Prostate Int2021https://conductscience.org/library/papers/34692585PubMed
34350976Degarelix for treating advanced hormone-sensitive prostate cancer.Cochrane Database Syst Rev2021https://conductscience.org/library/papers/34350976PubMed
31746656Surgical versus Medical Castration for Metastatic Prostate Cancer: Use and Overall Survival in a National Cohort.J Urol2020https://conductscience.org/library/papers/31746656PubMed
31194882Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer.Cochrane Database Syst Rev2019https://conductscience.org/library/papers/31194882PubMed
30830274Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.World J Urol2020https://conductscience.org/library/papers/30830274PubMed
30648519Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer who Underwent Orchiectomy: A Systematic Review and Metaanalysis.Curr Clin Pharmacol2019https://conductscience.org/library/papers/30648519PubMed
30637900Androgen deprivation therapy for prostate cancer and risk of dementia.BJU Int2019https://conductscience.org/library/papers/30637900PubMed
27586377Treatment of Metastatic Prostate Cancer in Older Adults.Curr Oncol Rep2016https://conductscience.org/library/papers/27586377PubMed
27390687Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis.Med J Islam Repub Iran2016https://conductscience.org/library/papers/27390687PubMed
27330919
The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis.
Springerplus2016https://conductscience.org/library/papers/27330919PubMed
27246172An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.Adv Ther2016https://conductscience.org/library/papers/27246172PubMed
27245503Prostate cancer: Combining endocrine treatment and radiotherapy: a bright future.Nat Rev Urol2016https://conductscience.org/library/papers/27245503PubMed
27222641Penile Rehabilitation Strategies Among Prostate Cancer Survivors.Rev Urol2015https://conductscience.org/library/papers/27222641PubMed

See all 21 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24979481

GET https://conductscience.org/api/papers/v1/24979481/references?page=2